PURPOSE: Long-term central venous catheters (CVCs) are often used in patients with cancer to facilitate venous access to administer intravenous fluids and chemotherapy. CVCs can also be a source of bloodstream infections, although this risk is not well understood. We examined the impact of long-term CVC use on infection risk, independent of other risk factors such as chemotherapy, in a population-based cohort of patients with cancer. PATIENTS AND METHODS: We conducted a retrospective analysis using SEER-Medicare data for patients age > 65 years diagnosed from 2005 to 2007 with invasive colorectal, head and neck, lung, or pancreatic cancer, non-Hodgkin lymphoma, or invasive or noninvasive breast cancer. Cox proportional hazards regression was used to examine the relationship between CVC use and infections, with CVC exposure as a time-dependent predictor. We used multivariable analysis and propensity score methods to control for patient characteristics. RESULTS: CVC exposure was associated with a significantly elevated infection risk, adjusting for demographic and disease characteristics. For patients with pancreatic cancer, risk of infections during the exposure period was three-fold greater (adjusted hazard ratio [AHR], 2.93; 95% CI, 2.58 to 3.33); for those with breast cancer, it was six-fold greater (AHR, 6.19; 95% CI, 5.42 to 7.07). Findings were similar when we accounted for propensity to receive a CVC and limited the cohort to individuals at high risk of infections. CONCLUSION: Long-term CVC use was associated with an increased risk of infections for older adults with cancer. Careful assessment of the need for long-term CVCs and targeted strategies for reducing infections are critical to improving cancer care quality.
PURPOSE: Long-term central venous catheters (CVCs) are often used in patients with cancer to facilitate venous access to administer intravenous fluids and chemotherapy. CVCs can also be a source of bloodstream infections, although this risk is not well understood. We examined the impact of long-term CVC use on infection risk, independent of other risk factors such as chemotherapy, in a population-based cohort of patients with cancer. PATIENTS AND METHODS: We conducted a retrospective analysis using SEER-Medicare data for patients age > 65 years diagnosed from 2005 to 2007 with invasive colorectal, head and neck, lung, or pancreatic cancer, non-Hodgkin lymphoma, or invasive or noninvasive breast cancer. Cox proportional hazards regression was used to examine the relationship between CVC use and infections, with CVC exposure as a time-dependent predictor. We used multivariable analysis and propensity score methods to control for patient characteristics. RESULTS: CVC exposure was associated with a significantly elevated infection risk, adjusting for demographic and disease characteristics. For patients with pancreatic cancer, risk of infections during the exposure period was three-fold greater (adjusted hazard ratio [AHR], 2.93; 95% CI, 2.58 to 3.33); for those with breast cancer, it was six-fold greater (AHR, 6.19; 95% CI, 5.42 to 7.07). Findings were similar when we accounted for propensity to receive a CVC and limited the cohort to individuals at high risk of infections. CONCLUSION: Long-term CVC use was associated with an increased risk of infections for older adults with cancer. Careful assessment of the need for long-term CVCs and targeted strategies for reducing infections are critical to improving cancer care quality.
Authors: J S Groeger; A B Lucas; H T Thaler; H Friedlander-Klar; A E Brown; T E Kiehn; D Armstrong Journal: Ann Intern Med Date: 1993-12-15 Impact factor: 25.391
Authors: Sharon B Wright; W Charles Huskins; Rachel S Dokholyan; Donald A Goldmann; Richard Platt Journal: Infect Control Hosp Epidemiol Date: 2003-12 Impact factor: 3.254
Authors: Charles A Schiffer; Pamela B Mangu; James C Wade; Dawn Camp-Sorrell; Diane G Cope; Bassel F El-Rayes; Mark Gorman; Jennifer Ligibel; Paul Mansfield; Mark Levine Journal: J Clin Oncol Date: 2013-03-04 Impact factor: 44.544
Authors: Gregory S Cooper; Beth Virnig; Carrie N Klabunde; Nicola Schussler; Jean Freeman; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Joan L Warren; Linda C Harlan; Angela Fahey; Beth A Virnig; Jean L Freeman; Carrie N Klabunde; Gregory S Cooper; Kevin B Knopf Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Beth A Virnig; Joan L Warren; Gregory S Cooper; Carrie N Klabunde; Nicola Schussler; Jean Freeman Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Allison Lipitz-Snyderman; Elena B Elkin; Coral L Atoria; Camelia S Sima; Andrew S Epstein; Victoria Blinder; Kent A Sepkowitz; Peter B Bach Journal: Med Care Date: 2015-07 Impact factor: 2.983
Authors: Allison Lipitz-Snyderman; Qinli Ma; Michael F Pollack; John Barron; Elena B Elkin; Peter B Bach; Jennifer L Malin Journal: J Oncol Pract Date: 2015-08-11 Impact factor: 3.840
Authors: Francesco Grossi; Piotr Jaśkiewicz; Marion Ferreira; Grzegorz Czyżewicz; Dariusz Kowalski; Libero Ciuffreda; Ramon Garcia-Gomez; Salvatore Caruso; Joaquim Bosch-Barrera; Stéphanie Gautier; Christine Ta Thanh Minh; Sébastien Henriet; Gilberto de Castro Journal: Ther Adv Med Oncol Date: 2021-07-16 Impact factor: 8.168